Leukemia, Prolymphocytic, T-Cell clinical trials
The registry lists 30 studies for Leukemia, Prolymphocytic, T-Cell across more than 10 countries. 8 are recruiting or about to start. 8 of them are mainly about Leukemia, Prolymphocytic, T-Cell (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-05.
Get an email when these change. Save the Leukemia, Prolymphocytic, T-Cell studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Fred Hutchinson Cancer Center (5) · M.D. Anderson Cancer Center (4) · Ohio State University Comprehensive Cancer Center (3) · German CLL Study Group (2) · Memorial Sloan Kettering Cancer Center (2) · Washington University School of Medicine (1) · Tesaro, Inc. (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
What is being tested here
Drugs under test in Leukemia, Prolymphocytic, T-Cell studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Ruxolitinib | 2 | 0 | 3 |
| Venetoclax | 2 | 0 | 3 |
| Duvelisib | 1 | 0 | 2 |
| Cladribine | 1 | 0 | 1 |
| Nexatoclax | 1 | 0 | 1 |
| Alrizomadlin | 1 | 0 | 1 |
| Mycophenolic Acid | 0 | 1 | 4 |
| Fludarabine | 0 | 0 | 4 |
| Cyclophosphamide | 0 | 0 | 3 |
| Fludarabine phosphate | 0 | 0 | 3 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open · JAK inhibitors 2 open · Antimetabolites 1 open · mTOR inhibitors 3 · Alkylating agents 3
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 4
- Dec 2026Registry of the German CLL Study Group · German CLL Study Group
- Dec 2026Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. · Newave Pharmaceutical Inc
- Aug 2027A Study of Ruxolitinib and Duvelisib in People With Lymphoma · Memorial Sloan Kettering Cancer Center
- Oct 2027Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · Ohio State University Comprehensive Cancer Center
Who these studies take
Of the 8 Leukemia, Prolymphocytic, T-Cell studies recruiting now, 7 (88%) set no upper age limit and 0 (0%) stop at 75 or younger. 3 (38%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (25%) | 2 (25%) |
| 18 | 8 (100%) | 8 (100%) |
| 30 | 8 (100%) | 8 (100%) |
| 40 | 8 (100%) | 8 (100%) |
| 50 | 8 (100%) | 8 (100%) |
| 65 | 8 (100%) | 8 (100%) |
| 75 | 8 (100%) | 8 (100%) |
| 85 | 8 (100%) | 8 (100%) |
Across all 30 studies, recruiting or not: 17% stop at 75 or younger and 3% at 65; 30% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 30 of 30. search them.
- Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic LeukemiaRecruitingNCT07311746Phase 1/21 country
- Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaRecruitingNCT07356245Phase 21 country
- Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)RecruitingNCT06810778Phase 1/21 country
- A Registry for People With T-cell LymphomaRecruitingNCT059781411 country
- Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.RecruitingNCT04771572Phase 11 country
- Registry of the German CLL Study GroupRecruitingNCT028636921 country
- A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLRecruitingNCT04496349Phase 21 country
- Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T CellsRecruitingNCT06420076Phase 1/21 country
- A Study of Ruxolitinib and Duvelisib in People With LymphomaActive, not recruitingNCT05010005Phase 11 country
- Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older PatientsActive, not recruitingNCT05823571Phase 11 country
- Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic MalignanciesSuspendedNCT05377827Phase 11 country
- Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell TransplantCompletedNCT01231412Phase 33 countries
- Romidepsin Maintenance After Allogeneic Stem Cell TransplantationCompletedNCT02512497Phase 11 country
- Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid TumorsCompletedNCT05225584Phase 11 country
- Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With AlemtuzumabCompletedNCT04312841Phase 21 country
- Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory LeukemiaTerminatedNCT04526795Phase 11 country
- Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic LeukemiaCompletedNCT03989466Phase 11 country
- A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic LeukemiaCompletedNCT03873493Phase 29 countries
- Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)CompletedNCT02689453Phase 11 country
- Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies MalignanciesStatus unknownNCT04823091Phase 11 country
- Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)CompletedNCT01186640Phase 21 country
- Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid MalignanciesCompletedNCT01094860Phase 11 country
- Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory LymphomaCompletedNCT00005803Phase 1/22 countries
- Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantCompletedNCT01251575Phase 22 countries
- Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic LeukemiaCompletedNCT01008462Phase 21 country
- Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LeukemiaCompletedNCT00060424Phase 22 countries
- CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and LymphomaStatus unknownNCT02742727Phase 1/21 country
- Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)CompletedNCT00124189Phase 11 country
- Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory LymphomaTerminatedNCT00671112Phase 11 country
- A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)CompletedNCT00749502Phase 1